This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

AVEO Pharmaceuticals Croissance future

Future contrôle des critères 5/6

Informations clés

123.0%

Taux de croissance des bénéfices

122.8%

Taux de croissance du BPA

Biotechs croissance des bénéfices	35.4%
Taux de croissance des recettes	36.2%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

DB:VPA1 - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2024	214	48	N/A	N/A	1
12/31/2023	162	12	N/A	N/A	1
12/31/2022	110	-24	N/A	N/A	1
9/30/2022	94	-29	-23	-23	N/A
6/30/2022	79	-36	-31	-31	N/A
3/31/2022	61	-41	-47	-47	N/A
12/31/2021	42	-53	-57	-57	N/A
9/30/2021	26	-58	-58	-58	N/A
6/30/2021	14	-56	-56	-56	N/A
3/31/2021	7	-49	-45	-45	N/A
12/31/2020	6	-36	-38	-38	N/A
9/30/2020	6	-29	-33	-32	N/A
6/30/2020	28	-4	-8	-8	N/A
3/31/2020	28	0	-6	-6	N/A
12/31/2019	29	9	-3	-3	N/A
9/30/2019	30	36	-2	-2	N/A
6/30/2019	6	-3	-24	-24	N/A
3/31/2019	6	4	-27	-27	N/A
12/31/2018	5	-5	-25	-25	N/A
9/30/2018	4	-24	-22	-22	N/A
6/30/2018	6	-28	-22	-22	N/A
3/31/2018	6	-65	-20	-20	N/A
12/31/2017	8	-65	-19	-19	N/A
9/30/2017	8	-74	-23	-23	N/A
6/30/2017	4	-53	-29	-29	N/A
3/31/2017	4	-28	-26	-26	N/A
12/31/2016	3	-27	-31	-31	N/A
9/30/2016	6	-28	-24	-24	N/A
6/30/2016	20	-15	N/A	-6	N/A
3/31/2016	20	-12	N/A	-13	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: VPA1 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.03%).

Bénéfices vs marché: VPA1 is forecast to become profitable over the next 3 years, which is considered above average market growth.

Croissance élevée des bénéfices: VPA1 is expected to become profitable in the next 3 years.

Chiffre d'affaires vs marché: VPA1's revenue (36.2% per year) is forecast to grow faster than the German market (3.8% per year).

Croissance élevée des revenus: VPA1's revenue (36.2% per year) is forecast to grow faster than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if VPA1's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

AVEO Pharmaceuticals Croissance future

Future contrôle des critères 5/6

Informations clés

Mises à jour récentes de la croissance future

Aveo Pharmaceuticals, Inc. Withdraws Earnings Guidance for the Year 2022

AVEO Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2022

Recent updates

LG Chem, Ltd. (KOSE:A051910) completed the acquisition of AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO) from a group of shareholders.

AVEO Oncology Appoints Martin Birkhofer as Its Chief Medical Officer

Insufficient new directors

Third quarter 2022 earnings released: US$0.094 loss per share (vs US$0.30 loss in 3Q 2021)

Aveo Pharmaceuticals, Inc. Withdraws Earnings Guidance for the Year 2022

AVEO Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

AVEO Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.40 loss in 2Q 2021)

AVEO Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from Russell Microcap Value Index

AVEO Oncology Announces Updated National Comprehensive Cancer Network Clinical Practice Guidelines Elevate Fotivda (Tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced Renal Cell Carcinoma Patients

First quarter 2022 earnings released: US$0.30 loss per share (vs US$0.81 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

AVEO Pharmaceuticals, Inc. Announces Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® in Third- and Fourth-Line Renal Cell Carcinoma

Aveo Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium

Aveo Oncology Highlights Recent Progress and 2022 Outlook

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.33 loss in 3Q 2020)

AVEO Oncology Announces Ficlatuzumab Grants Fast Track Designation by the U.S. FDA

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from Russell 3000E Value Index

AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC

CANbridge Life Sciences Ltd. and AVEO Pharmaceuticals, Inc. Terminate Collaboration and License Agreement

AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate Fotivda® in Combination with Opdivo® in Pivotal Phase 3 Tinivo-2 Trial in Io Relapsed Renal Cell Carcinoma

AVEO Oncology Announces U.S. FDA Approval of FOTIVDA (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma

AVEO Oncology Announces Appointment of Mike Ferraresso to Chief Commercial Officer

AVEO Pharmaceuticals, Inc. Appoints Corinne Epperly as Member of the Board and to Its Nominating and Governance Committee and Compensation Committee

AVEO Pharmaceuticals, Inc. Announces the Departure of Karuna Rubin, Senior Vice President and General Counsel

AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI® (Durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma

AVEO Pharmaceuticals, Inc. Announces Management Changes

AVEO Oncology and EUSA Pharma Announce Annals of Oncology Publication of Data from Phase 1b/2 TiNivo Study in Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc. announced that it has received $7.499997 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from S&P Global BMI Index

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance